36.18
-1.13 (-3.03%)
| Previous Close | 37.31 |
| Open | 37.05 |
| Volume | 3,231,837 |
| Avg. Volume (3M) | 3,899,928 |
| Market Cap | 3,555,661,824 |
| Price / Earnings (Forward) | 25.97 |
| Price / Sales | 1.93 |
| Price / Book | 3.42 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sarepta Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.44% |
| % Held by Institutions | 90.38% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Needham, 245.50%) | Buy |
| Median | 98.00 (170.87%) | |
| Low | 40.00 (HC Wainwright & Co., 10.56%) | Hold |
| Average | 90.08 (148.98%) | |
| Total | 10 Buy, 3 Hold | |
| Avg. Price @ Call | 40.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 06 Jun 2025 | 80.00 (121.12%) | Buy | 43.01 |
| 20 Mar 2025 | 80.00 (121.12%) | Hold | 73.45 | |
| HC Wainwright & Co. | 22 May 2025 | 40.00 (10.56%) | Hold | 38.79 |
| 07 May 2025 | 40.00 (10.56%) | Hold | 36.72 | |
| JP Morgan | 20 May 2025 | 84.00 (132.17%) | Buy | 39.99 |
| Wells Fargo | 08 May 2025 | 100.00 (176.40%) | Buy | 36.52 |
| 11 Apr 2025 | 115.00 (217.86%) | Buy | 51.03 | |
| Cantor Fitzgerald | 07 May 2025 | 81.00 (123.88%) | Buy | 36.72 |
| 19 Mar 2025 | 163.00 (350.53%) | Buy | 79.97 | |
| Goldman Sachs | 07 May 2025 | 100.00 (176.40%) | Buy | 36.72 |
| Guggenheim | 07 May 2025 | 98.00 (170.87%) | Buy | 36.72 |
| Morgan Stanley | 07 May 2025 | 113.00 (212.33%) | Buy | 36.72 |
| 11 Apr 2025 | 182.00 (403.04%) | Buy | 51.03 | |
| Needham | 07 May 2025 | 125.00 (245.49%) | Buy | 36.72 |
| 03 Apr 2025 | 183.00 (405.80%) | Buy | 58.61 | |
| Oppenheimer | 07 May 2025 | 123.00 (239.97%) | Buy | 36.72 |
| Piper Sandler | 07 May 2025 | 70.00 (93.48%) | Buy | 36.72 |
| 21 Apr 2025 | 110.00 (204.04%) | Buy | 55.23 | |
| RBC Capital | 07 May 2025 | 58.00 (60.31%) | Hold | 36.72 |
| 31 Mar 2025 | 87.00 (140.46%) | Hold | 63.82 | |
| Deutsche Bank | 19 Mar 2025 | 99.00 (173.63%) | Hold | 79.97 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |